Skip to Main content Skip to Navigation
Journal articles

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Javed Butler 1 Stefan Anker 2, 3, 4 Gerasimos Filippatos 5 Muhammad Khan 1 João Ferreira 6, 7, 8, 9 Stuart Pocock 10 Nadia Giannetti 11 James Januzzi 12 Ileana Piña 13 Carolyn Lam 14 Piotr Ponikowski 15 Naveed Sattar 16 Subodh Verma 17 Martina Brueckmann 18, 19 Waheed Jamal 18 Ola Vedin 20 Barbara Peil 21 Cordula Zeller 21 Faiez Zannad 6, 7, 8, 9 Milton Packer 22, 23
Abstract : Aims: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. Methods and results: Health status was assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence of baseline KCCQ-CSS (analyzed by tertiles) on the effect of empagliflozin on major outcomes was examined using Cox proportional hazards models. Responder analyses were performed to assess the odds of improvement and deterioration in KCCQ scores related to treatment with empagliflozin. Empagliflozin reduced the primary outcome of cardiovascular death or heart failure hospitalization regardless of baseline KCCQ-CSS tertiles [hazard ratio (HR) 0.83 (0.68-1.02), HR 0.74 (0.58-0.94), and HR 0.61 (0.46-0.82) for <62.5, 62.6-85.4, and ≥85.4 score tertiles, respectively; P-trend = 0.10]. Empagliflozin improved KCCQ-CSS, total symptom score, and overall summary score at 3, 8, and 12 months. More patients on empagliflozin had ≥5-point [odds ratio (OR) 1.20 (1.05-1.37)], 10-point [OR 1.26 (1.10-1.44)], and 15-point [OR 1.29 (1.12-1.48)] improvement and fewer had ≥5-point [OR 0.75 (0.64-0.87)] deterioration in KCCQ-CSS at 3 months. These benefits were sustained at 8 and 12 months and were similar for other KCCQ domains. Conclusion: Empagliflozin improved cardiovascular death or heart failure hospitalization risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up.
Complete list of metadata

https://hal.univ-lorraine.fr/hal-03115141
Contributor : Erwan Bozec Connect in order to contact the contributor
Submitted on : Tuesday, January 19, 2021 - 2:15:14 PM
Last modification on : Tuesday, October 19, 2021 - 2:18:09 PM
Long-term archiving on: : Tuesday, April 20, 2021 - 7:32:34 PM

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Collections

Citation

Javed Butler, Stefan Anker, Gerasimos Filippatos, Muhammad Khan, João Ferreira, et al.. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, Oxford University Press (OUP): Policy B, 2021, ⟨10.1093/eurheartj/ehaa1007⟩. ⟨hal-03115141⟩

Share

Metrics

Record views

174

Files downloads

347